Regeneron registers Phase 3 LINKER-AL1 trial of linvoseltamab for AL amyloidosisOct 30Weekly roundup, 6 itemscemiplimab-rwlcdupilumabUpdated
Alnylam posts Q3 2026 results, widens nucresiran trial, advances Huntington's programOct 29Quarterly updateAlnylam Pharmaceuticalsnucresiran
Regeneron registers Phase 1b hemodialysis study, Phase 1 Graves' disease trialOct 9Weekly roundup, 6 itemsamrecibartbortezomib
FDA approves REMS-related supplement for Lynozyfic (linvoseltamab-gcpt)Jul 31Regulatory decisionlinvoseltamab-gcptRegeneron Pharmaceuticals
Regeneron reports Q2 2026 results, cemdisiran filings accepted, fianlimab trial missesJul 30Quarterly updatecemdisiranfianlimab